About this trial
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)
Subjects of all genders with a full capacity of consent
Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement
Subjects of at least 18 years of age at the time of inclusion
Disqualifiers
Refusal to sign the informed consent
Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion
Active cancer
Pregnant women
Trial population
Subjects with a neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) and gender- and age-matched healthy controls.
Trial design
Cohort
Prospective
Treatments tested in this trial
Observational study with sample and data collection
Other interventionObservational study with sample and data collection
Treatment groups
Trial outcomes
Primary outcomes
1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls
1.1. Samples will be aliquoted and stored according to the highest standards at the IBBL for future research.
2. Stratification of parkinsonism into subtypes and definition of individual progression trajectories of PD.
2.1. Identify PD patients' subgroups with a similar pattern of disease progression. datasets.
Determine Parkinson's disease biomarker signatures
3.1. Identify new and early diagnostic biomarkers
Develop a mechanistic understanding of the disease
4.1. Understand the mechanisms of PD pathogenesis.
Secondary outcomes
Inform future studies testing new therapies for Parkinson's disease
1.1. Enable future studies, such as clinical trials, by sharing the findings of mechanisms of PD pathogenesis and identifying new therapeutic targets.
Harmonization of data with international Parkinson's disease cohort studies
2.1. Data collected in this study will be harmonized with the international PD research community through an open-source digital platform.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Luxembourg Institute of Health
Lead sponsor
University of Luxembourg
Collaborator
Laboratoire National de Santé (LNS)
Collaborator
Centre Hospitalier du Luxembourg
Collaborator